Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.62 |
| ▸ | PDE5A | O76074 | 2/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.56 |
| ▸ | PDE8A | O60658 | 1/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.56 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.56 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.56 |
| ▸ | PDE1A | P54750 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18745385 | 0.87 | PDE4A (0.73) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL4919006 | 0.87 | PDE4A (0.73) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL8248711 | 0.86 | PDE4A (0.78) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL4924402 | 0.76 | PDE4A (0.72) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL18380624 | 0.76 | PDE4A (0.72) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL7874805 | 0.74 | PDE4A (0.57) | PDE4APDE5APDE3BPDE4BPDE4C | |
| SCHEMBL4922144 | 0.73 | PDE4A (1.00) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL18745384 | 0.73 | PDE4A (1.00) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL18844227 | 0.72 | PDE4A (0.77) | PDE4APDE5APDE2APDE8APDE3B | |
| SCHEMBL19134017 | 0.72 | PDE4A (1.00) | PDE4APDE5APDE2APDE8APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682355-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682355-B2 | Uses | CNTN1, BDNF, SMPD1 | PDE4A 44/4885PDE5A 14/4885PDE2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.